Allogene Therapeutics
Eike Zimmermann has extensive work experience in the pharmaceutical industry. The most recent position held was as the Senior Director Product Quality Lead at Allogene Therapeutics, starting in May 2019. Prior to this, Zimmermann worked at Boehringer Ingelheim for seven years, initially as a Senior Scientist from December 2012 to August 2013, then as an Associate Director from August 2013 onwards, and eventually as a Senior Associate Director from May 2018 onwards. Before Boehringer Ingelheim, Zimmermann worked at Bayer for five years, serving as the Head of Protein Chemistry/Chemistry Assay Development from September 2012 to December 2012, and as a Staff Development Scientist from April 2007 to September 2012. Zimmermann's career began at Berlex Biosciences in 2001, where they worked as a Postdoc from June 2001 to November 2002, and as a Scientist from December 2002 to March 2007.
Eike Zimmermann completed a Master's degree in Pharmaceutical Sciences at The University of Bonn from 1992 to 1999. Following this, from 1998 to 2001, Zimmermann pursued a Doctor of Philosophy (PhD) in Pharmaceutical Sciences at Freie Universität Berlin.
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.